To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we
performed a population-based observational study. The study involved 307 patients treated …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …

Objective To explore the efficacy and safety of erlotinib monotherapy for advanced non-
small cell lung cancer (NSCLC). Methods Totally 50 patients with advanced NSCLC …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …

Purpose Erlotinib is the first epidermal growth factor receptor–tyrosine kinase inhibitor
shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) …

Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a
significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of …

Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has
shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell …